Affinity Asset Advisors, LLC Increases Stake in Sutro Biopharma, Inc.

Affinity Asset Advisors, LLC, along with Affinity Healthcare Fund, LP, has filed a Schedule 13G with the SEC, disclosing an increased stake in Sutro Biopharma, Inc. As of October 23, 2025, Affinity Asset Advisors, LLC beneficially owns 6,583,772 shares of Sutro Biopharma's Common Stock, representing 7.77% of the outstanding shares. This marks a significant increase from previous holdings, with the value of the stake rising by 1,321.22% and the number of shares increasing by 774.66%. The filing indicates that both entities share voting and dispositive power over these shares. The filing was made under Rule 13d-1(c) and was signed by Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer of both entities.